Terumo Aortic’s Treo Endovascular Device Approved and Launched in Japan

October 22, 2021—Terumo Aortic announced the regulatory approval and the commercial launch of the Treo abdominal aortic stent graft system in Japan. The Japanese Pharmaceuticals and Medical Devices Agency approved the Treo device for the treatment of patients with abdominal aortic aneurysms. Treo received CE Mark approval in 2015 and FDA approval in 2020, noted the company.

In Japan, the first commercial implantation of the Treo endovascular device was performed by Takao Ohki, MD, Chairman of the Department of Surgery, Professor and Chief of the Division of Vascular Surgery, at Jikei University School of Medicine, in Tokyo, Japan.

“The procedure was very successful, the device performed well, and the patient is making a good recovery,” commented Professor Ohki in the company’s press release.

“The major concerns in endovascular surgery are stent migration and endoleaks,” explained Professor Ohki. “The Treo device provides both suprarenal and infrarenal fixation allowing for distribution of the stent graft fixation in two different anatomical levels and is expected to result in superior long-term outcomes. In addition, the Treo device is sophisticated and very user friendly with a smooth, kink-resistant detachable sheath that definitely improves the accuracy and safety of the procedure.”